Startup Fights Superbugs, Antibiotic Resistance with Rapid Testing
Published by nocamels.com on July 21, 2024.
There’s a common situation that occurs during a doctor’s visit. The patient comes in with an ailment, perhaps it’s a cough, a congested chest or ear ache. The doctor raises possibilities of what could be causing the sickness – pneumonia, strep throat, an ear infection and so on. Chests are listened to, ears are examined, noses are swabbed and some tests are sent off to the lab.
In the meantime, as the results may take days to come in, the doctor recommends that the patient get started on a round of antibiotics, making an educated guess to diagnose a possible bacterial infection and hoping to tackle it before it gets worse.
The doctor makes the best recommendation with the knowledge available at that moment.
Unfortunately, inefficient testing has led to the over-prescription of antibiotics, resulting in antimicrobial resistance (AMR), which is when bacteria become resistant to antibiotics.
According to the World Health Organization (WHO), there are 1.27 million deaths every year that are directly attributed to antimicrobial resistance, with the prediction that by 2050, AMR will be the cause of 10 million annual deaths worldwide.
To tackle this issue, Israeli medical technology startup NanoSynex has developed a rapid personalized diagnostic test, which will enable doctors to prescribe the correct antibiotics at the moment they are needed most.
Keep reading at nocamels.com.
NanoSynex Co-founders CEO Diane Abensur and COO Michelle Heymann are Technion alumnae. NanoSynex’s core technology was developed by Technion Professor Shulamit Levenberg, who now serves as the company’s Chief Scientific Advisor.